Evaluation of jaw pathologies of patients with medication-related osteonecrosis of the jaw using a computer program to assess the bone scan index: comparison of standardized uptake values with bone SPECT/CT

被引:0
|
作者
Shirai, Ai [1 ]
Ogura, Ichiro [1 ,2 ]
机构
[1] Course Appl Sci, Quantitat Diagnost Imaging, Field Oral & Maxillofacial Imaging & Histopathol D, Niigata, Japan
[2] Nippon Dent Univ, Sch Life Dent Niigata, Dept Oral & Maxillofacial Radiol, Niigata, Japan
关键词
bone metastases; bone scan index; medication-related osteonecrosis of the jaw; osteoporosis; single-photon emission-computed tomography; SCINTIGRAPHY; CANCER;
D O I
10.1097/MNM.0000000000001896
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectivesThe aim of this study is to investigate the jaw pathologies of patients with medication-related osteonecrosis of the jaw (MRONJ) using a computer program to assess the bone scan index (BSI), especially comparison of standardized uptake values (SUVs) with bone single-photon emission-computed tomography/computed tomography (SPECT/CT).MethodsSixty-three patients with MRONJ underwent bone SPECT/CT in this prospective study. BSI and high-risk hot spot as bone metastases in the patients with MRONJ were evaluated using a computer program for BSI that scanned SPECT/CT and automatically defined the data. The maximum and mean SUVs with SPECT/CT were obtained using commercially available software. Statistical analyses were performed by Pearson chi-square test, Mann-Whitney U-test, or one-way analysis of variance with Tukey's honestly significant difference test. A P value lower than 0.05 was considered statistically significant.ResultsThe maximum and mean SUVs for a high-risk hot spot of the jaw with MRONJ [28.2 +/- 10.2 and 11.7 +/- 3.8; n = 6 (6/63 : 9.5%)] were significantly higher than those for a low-risk hot spot [18.5 +/- 6.4 and 6.2 +/- 1.9; n = 23 (23/63 : 36.5%)] and no-risk hot spot [14.2 +/- 9.4 and 5.3 +/- 5.1; n = 34 (34/63 : 54.0%)], respectively.ConclusionThe computer program for BSI indicated that 9.5% of the jaw with MRONJ were false positive of bone metastases. The study suggests that high-risk hot spots of the jaw with MRONJ depend on the SUVs.
引用
收藏
页码:1007 / 1012
页数:6
相关论文
共 50 条
  • [21] The Role of Bone Grafts in Preventing Medication-Related Osteonecrosis of the Jaw: Histomorphometric, Immunohistochemical, and Clinical Evaluation in Animal Model
    da Silva, Jonathan Ribeiro
    Balbas, Maria Cristina de Moraes
    Correa, Caroline Agueda
    Zanela, Manuella
    Okamoto, Roberta
    Pereira, Rodrigo dos Santos
    Homsi, Nicolas
    Hochuli-Vieira, Eduardo
    CRANIOMAXILLOFACIAL TRAUMA & RECONSTRUCTION, 2022, 15 (04) : 304 - 311
  • [22] Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
    Hiroaki Ikesue
    Kohei Doi
    Mayu Morimoto
    Masaki Hirabatake
    Nobuyuki Muroi
    Shinsuke Yamamoto
    Toshihiko Takenobu
    Tohru Hashida
    Supportive Care in Cancer, 2022, 30 : 2341 - 2348
  • [23] Bone resection methods in medication-related osteonecrosis of the jaw in the mandible: An investigation of 206 patients undergoing surgical treatment
    Suyama, Koki
    Otsuru, Mitsunobu
    Nakamura, Norio
    Morishita, Kota
    Miyoshi, Taro
    Omori, Keisuke
    Miura, Kei-ichiro
    Soutome, Sakiko
    Hayashida, Saki
    Rokutanda, Satoshi
    Umeda, Masahiro
    JOURNAL OF DENTAL SCIENCES, 2024, 19 (03) : 1758 - 1769
  • [24] The first quantitative histomorphological analyses of bone vitality and inflammation in surgical specimens of patients with medication-related osteonecrosis of the jaw
    Mamilos, Andreas
    Spoerl, Steffen
    Spanier, Gerrit
    Ettl, Tobias
    Brochhausen, Christoph
    Klingelhoeffer, Christoph
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2021, 50 (01) : 76 - 84
  • [25] The high risk of the development of medication-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis: A case report
    Cheng, Feng-Chou
    Chen, Mu-Hsiung
    Chang, Chun-Pin
    JOURNAL OF DENTAL SCIENCES, 2024, 19 (04) : 2448 - 2451
  • [26] Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis
    Ichiro Ogura
    Eizaburo Kobayashi
    Ken Nakahara
    Kensuke Igarashi
    Maiko Haga-Tsujimura
    Hiroo Toshima
    Annals of Nuclear Medicine, 2019, 33 : 776 - 782
  • [27] Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis
    Ogura, Ichiro
    Kobayashi, Eizaburo
    Nakahara, Ken
    Igarashi, Kensuke
    Haga-Tsujimura, Maiko
    Toshima, Hiroo
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (10) : 776 - 782
  • [28] Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis
    Ikesue, Hiroaki
    Doi, Kohei
    Morimoto, Mayu
    Hirabatake, Masaki
    Muroi, Nobuyuki
    Yamamoto, Shinsuke
    Takenobu, Toshihiko
    Hashida, Tohru
    SUPPORTIVE CARE IN CANCER, 2022, 30 (03) : 2341 - 2348
  • [29] Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
    Hiroaki Ikesue
    Kohei Doi
    Mayu Morimoto
    Masaki Hirabatake
    Nobuyuki Muroi
    Shinsuke Yamamoto
    Toshihiko Takenobu
    Tohru Hashida
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 871 - 877
  • [30] Retrospective analysis of bacterial colonization of necrotic bone and antibiotic resistance in 98 patients with medication-related osteonecrosis of the jaw (MRONJ)
    Ewald, Florian
    Wuesthoff, Falk
    Koehnke, Robert
    Friedrich, Reinhard E.
    Gosau, Martin
    Smeets, Ralf
    Rohde, Holger
    Assaf, Alexandre T.
    CLINICAL ORAL INVESTIGATIONS, 2021, 25 (05) : 2801 - 2809